MP040: T1 substage in superficial bladder urothelial carcinoma can predict progression free survival
  • 2019-06-28,
  • 上傳者: TUA人資客服組,
  •  0
T1 substage in superficial bladder urothelial carcinoma can predict progression free survival
Yu-Kuang Chen1, Tzu-Ping Lin1,2, Yen-Hwa Chang1,2, Junne Yih Kuo1,2,
Hsiao-Jen Chung1,2, Howard H.H Wu1,2, Eric Yi-Hsiu Huang1,2, Chi-Cheh Lin1,2,
Y.H. Fan1,2, I-shen Huang1,2, Shih-Yen Lu3, Alex T.L. Lin1,2, William J. Huang1,2
Department of Urology, Taipei Veterans General Hospital, Taipei, Taiwan1,
Department of Urology, School of Medicine and Shu-Tien Urological Science Research Center, National Yang-Ming University, Taipei, Taiwan2, Department of Surgery, Taipei Veterans General Hospital Hsinchu branch, Hsinchu, Taiwan3
     For urothelial bladder cancer, the depth of tumor invasion and tumor grade affect prognosis significantly. Among superficial  urothelial carcinomas (UC) of the urinary bladder, T1 UC have much variable clinical presentation and course, but there is no consensus in substaging system in these patients. We analyzed the outcomes of focal and extensive T1 substaging according to the depth of lamina propria invasion (1.0 mm as cut off value) in out institute.
Materials and Methods
        From 2007 to 2015, patients with pathology report of focal (≤ 1.0 mm) and extensive (>1.0 mm) T1 high grade bladder urothelial carcinoma (UC) were enrolled retrospectively. Patients with history of primary (pure) CIS, muscle invasive or upper tract UC were excluded. Clinical variables including demographic data, pathological grading and staging, recurrence was retrieved in hospital information system. The definition of recurrence was reappearance of UC in the bladder, and progression was advancing in stage, metastasis or death caused by UC. Outcomes including recurrence free survival, progression free survival, cancer specific and overall survival were analyzed with Kaplan-Meier method.
A total of 363 patients were in the cohort, with 55-month follow-up in average. The mean age was 74 (±12.0) years old. One hundred and thirty-eight (38%) patient were classified as T1 focal substage, and 225 patients were T1 extensive. There were no significant differences in the demographic variables including sex, age, smoking or medical comorbidity between the two groups. With Kaplan-Meier survival analysis, progression free survival was significant shorter (p=0.024, log-rank test) in T1 extensive group, but we were unable to demonstrate a difference in recurrence free survival (p=0.168), cancer specific (p=0.102) or overall (p=0.515) survival between two groups.
        In our single institute cohort, extensive T1 predicted shorter progression free survival as compared with focal T1.
訪客如要回應,請先 登入
    資料夾 :
    發表時間 :
    2019-06-28 23:05:57
    觀看數 :
    發表人 :
    部門 :
    QR Code :